The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $23.97 / share. This is a decrease of 15.26% from the prior estimate of $28.29 dated April 25, 2026. The ...
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the common stocks of companies expected to benefit from the development and use of science and ...
180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...
Gilead Sciences (GILD) announced that it has priced senior unsecured notes totaling $3B in a public offering. This includes $500M of 4.250% senior notes maturing in 2028, $1B of 4.400% senior notes ...
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results